Case Type: Mergers & Acquisitions

ZimVie Inc. (NASDAQ: ZIMV) related to its sale to an affiliate of ARCHIMED. Under the terms of the proposed transaction, ZimVie shareholders will receive $19.00 in cash per share.

iTeos Therapeutics, Inc. (NASDAQ: ITOS) related to its sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Concentra will acquire iTeos for $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; … Read more

Colombier Acquisition Corp. II (NYSE: CLBR) related to its merger with Metroplex Trading Company (“GrabAGun”). The proposed transaction is valued at $150 million with the current equity holders of GrabAGun receiving $100 million of stock in the combined company and $50 million of cash.

Goldenstone Acquisition Limited (OTCMKTS: GDST) related to its merger with Infintium Fuel Cell Systems, Inc. Upon completion of the proposed transaction, Infinitum Class A and Class B common stock will be converted into shares of Goldenstone common stock.

Veritex Holdings, Inc. (NASDAQ: VBTX) related to its sale to Huntington Bancshares Inc. Upon completion of the proposed transaction, Huntington will issue 1.95 shares for each outstanding share of Veritex.

Voyager Acquisition Corp. (NASDAQ: VACH) related to its merger with Veraxa Biotech AG. Upon completion of the proposed transaction, each Voyager Class A and B ordinary share will be cancelled and exchanged for one Class A ordinary share in the combined company

Augusta Gold Corp. (OTCMKTS: AUGG) related to its merger with AngloGold Ashanti Holdings, Inc. Upon completion of the proposed transaction, each outstanding share of Augusta will be converted in the right to receive CAD$1.70 in cash.

Onconetix, Inc. (NASDAQ: ONCO) related to its merger with Ocuvex Therapeutics, Inc. Upon completion of the proposed transaction, each share of Ocuvex will be exchanged for a number of Onconetix shares based on a defined exchange ratio, resulting in Ocuvex shareholders owning approximately 90% of the combined company and Onconetix shareholders owning approximately 10%.

Longevity Health Holdings, Inc. (NASDAQ: XAGE) related to its merger with 20/20 BioLabs, Inc. Upon completion of the proposed transaction, Longevity shareholders are expected to own approximately 49.9% of the combined company.

Waters Corporation (NYSE: WAT) related to its merger with BD and Company’s Biosciences and Diagnostic Solutions. Upon completion of the proposed transaction, existing Waters shareholders are expected to own approximately 60.8% of the combined company.